SEC Form 4 · accession 0001628280-26-057007
AbCellera Biologics Inc. · ABCL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Hayden
Director
Period of report
Aug 12, 2026
Accepted (ET)
Aug 14, 2026 · 11:50 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001703057
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Aug 12, 2026 | P | 46,387 | $10.37 | A | 1,319,784 | I | See footnote |
| Common Shares | holding | — | — | — | 118,245 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.25 to $10.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
- F2These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.